These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 34162872)

  • 1. Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer.
    Roper N; Velez MJ; Chiappori A; Kim YS; Wei JS; Sindiri S; Takahashi N; Mulford D; Kumar S; Ylaya K; Trindade C; Manukyan I; Brown AL; Trepel JB; Lee JM; Hewitt S; Khan J; Thomas A
    Nat Commun; 2021 Jun; 12(1):3880. PubMed ID: 34162872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1.
    Ito T; Kudoh S; Ichimura T; Fujino K; Hassan WA; Udaka N
    Hum Cell; 2017 Jan; 30(1):1-10. PubMed ID: 27785690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer.
    Taniguchi H; Chakraborty S; Takahashi N; Banerjee A; Caeser R; Zhan YA; Tischfield SE; Chow A; Nguyen EM; Villalonga ÁQ; Manoj P; Shah NS; Rosario S; Hayatt O; Qu R; de Stanchina E; Chan J; Mukae H; Thomas A; Rudin CM; Sen T
    Sci Adv; 2024 Sep; 10(39):eado4618. PubMed ID: 39331709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notch1 signaling controls cell proliferation, apoptosis and differentiation in lung carcinoma.
    Wael H; Yoshida R; Kudoh S; Hasegawa K; Niimori-Kita K; Ito T
    Lung Cancer; 2014 Aug; 85(2):131-40. PubMed ID: 24888228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer.
    Cai L; Liu H; Huang F; Fujimoto J; Girard L; Chen J; Li Y; Zhang YA; Deb D; Stastny V; Pozo K; Kuo CS; Jia G; Yang C; Zou W; Alomar A; Huffman K; Papari-Zareei M; Yang L; Drapkin B; Akbay EA; Shames DS; Wistuba II; Wang T; Johnson JE; Xiao G; DeBerardinis RJ; Minna JD; Xie Y; Gazdar AF
    Commun Biol; 2021 Mar; 4(1):314. PubMed ID: 33750914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer.
    Hong D; Knelson EH; Li Y; Durmaz YT; Gao W; Walton E; Vajdi A; Thai T; Sticco-Ivins M; Sabet AH; Jones KL; Schinzel AC; Bronson RT; Nguyen QD; Tolstorukov MY; Vivero M; Signoretti S; Barbie DA; Oser MG
    Cancer Res; 2022 Jan; 82(2):248-263. PubMed ID: 34810201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
    Hiatt JB; Sandborg H; Garrison SM; Arnold HU; Liao SY; Norton JP; Friesen TJ; Wu F; Sutherland KD; Rienhoff HY; Martins R; Houghton AM; Srivastava S; MacPherson D
    Clin Cancer Res; 2022 Oct; 28(20):4551-4564. PubMed ID: 35920742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathology of small cell lung cancer: Overview from studies on neuroendocrine differentiation regulated by ASCL1 and Notch signaling.
    Ito T
    Pathol Int; 2024 May; 74(5):239-251. PubMed ID: 38607250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study.
    Thomas A; Vilimas R; Trindade C; Erwin-Cohen R; Roper N; Xi L; Krishnasamy V; Levy E; Mammen A; Nichols S; Chen Y; Velcheti V; Yin F; Szabo E; Pommier Y; Steinberg SM; Trepel JB; Raffeld M; Young HA; Khan J; Hewitt S; Lee JM
    J Thorac Oncol; 2019 Aug; 14(8):1447-1457. PubMed ID: 31063862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
    Taniguchi H; Caeser R; Chavan SS; Zhan YA; Chow A; Manoj P; Uddin F; Kitai H; Qu R; Hayatt O; Shah NS; Quintanal Villalonga Á; Allaj V; Nguyen EM; Chan J; Michel AO; Mukae H; de Stanchina E; Rudin CM; Sen T
    Cell Rep; 2022 May; 39(7):110814. PubMed ID: 35584676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of CD38 in anti-tumor immunity of small cell lung cancer.
    Taniguchi H; Chavan SS; Chow A; Chan JM; Mukae H; Rudin CM; Sen T
    Front Immunol; 2024; 15():1348982. PubMed ID: 38533509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
    Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
    Ragavan M; Das M
    Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
    Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
    Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.
    Nabet BY; Hamidi H; Lee MC; Banchereau R; Morris S; Adler L; Gayevskiy V; Elhossiny AM; Srivastava MK; Patil NS; Smith KA; Jesudason R; Chan C; Chang PS; Fernandez M; Rost S; McGinnis LM; Koeppen H; Gay CM; Minna JD; Heymach JV; Chan JM; Rudin CM; Byers LA; Liu SV; Reck M; Shames DS
    Cancer Cell; 2024 Mar; 42(3):429-443.e4. PubMed ID: 38366589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer.
    Wagner AH; Devarakonda S; Skidmore ZL; Krysiak K; Ramu A; Trani L; Kunisaki J; Masood A; Waqar SN; Spies NC; Morgensztern D; Waligorski J; Ponce J; Fulton RS; Maggi LB; Weber JD; Watson MA; O'Conor CJ; Ritter JH; Olsen RR; Cheng H; Mukhopadhyay A; Can I; Cessna MH; Oliver TG; Mardis ER; Wilson RK; Griffith M; Griffith OL; Govindan R
    Nat Commun; 2018 Sep; 9(1):3787. PubMed ID: 30224629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC.
    Nguyen EM; Taniguchi H; Chan JM; Zhan YA; Chen X; Qiu J; de Stanchina E; Allaj V; Shah NS; Uddin F; Manoj P; Liu M; Cai SF; Levine R; Quintanal-Villalonga Á; Sen T; Chow A; Rudin CM
    J Thorac Oncol; 2022 Aug; 17(8):1014-1031. PubMed ID: 35691495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.